SAN LUIS OBISPO, Calif.--(BUSINESS WIRE)--FzioMed, Inc. (www.fziomed.com) announced that it has shipped the 400,000th unit of Oxiplex® gel. Oxiplex is approved outside the United States in 70 countries and is distributed under the brand names Oxiplex®, Oxiplex®/SP and MediShield™.
Oxiplex is an absorbable gel that is applied to spinal nerve roots during lumbar laminectomy, laminotomy and discectomy procedures for the treatment of herniated discs. Oxiplex creates a temporary physical barrier between adjacent tissues that protects against the effects of excessive fibrosis, inflammation and other irritants that can lead to recurrent postoperative pain.
Oxiplex has been shown in numerous clinical studies to improve the outcomes of spine surgery by reducing postoperative leg pain, back pain and neurological symptoms.
“Oxiplex, the world’s leading adhesion prevention device for spine surgery, continues to gain new approvals and users around the world every year,” said John Krelle, FzioMed’s President and Chief Executive Officer. “Since its introduction in 2002, multiple clinical studies and peer-reviewed articles have supported the safety and efficacy of Oxiplex; this profile is further enhanced by many companion products: Dynavisc to reduce fibrosis in tendon and peripheral nerve surgery; Oxiplex/AP for use in the gynecologic procedures; and Laresse, a dermal filler for the correction of facial lines and folds.”
FzioMed, Inc. is a privately held medical device company that develops, manufactures and markets absorbable surgical biomaterials based on its patented scientific technology. For more information, please visit www.fziomed.com
FzioMed®, Oxiplex®, Laresse®, and Dynavisc® are registered trademarks of FzioMed, Inc. MediShield™ is a registered trademark of Medtronic Sofamor Danek, Inc.